These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2341578)

  • 1. Binding of diltiazem to albumin, alpha 1-acid glycoprotein and to serum in man.
    Belpaire FM; Bogaert MG
    J Clin Pharmacol; 1990 Apr; 30(4):311-7. PubMed ID: 2341578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of alfentanil to human alpha 1-acid glycoprotein, albumin and serum.
    Belpaire FM; Bogaert MG
    Int J Clin Pharmacol Ther Toxicol; 1991 Mar; 29(3):96-102. PubMed ID: 2071261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Displacement of lidocaine from serum alpha 1-acid glycoprotein binding sites by basic drugs.
    Goolkasian DL; Slaughter RL; Edwards DJ; Lalka D
    Eur J Clin Pharmacol; 1983; 25(3):413-7. PubMed ID: 6628530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
    David BM; Ilett KF; Whitford EG; Stenhouse NS
    Br J Clin Pharmacol; 1983 Apr; 15(4):435-41. PubMed ID: 6849779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.
    Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE
    Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The acute changes in serum binding of disopyramide and flecainide after myocardial infarction.
    Caplin JL; Johnston A; Hamer J; Camm AJ
    Eur J Clin Pharmacol; 1985; 28(3):253-5. PubMed ID: 4007029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction.
    Routledge PA; Shand DG; Barchowsky A; Wagner G; Stargel WW
    Clin Pharmacol Ther; 1981 Aug; 30(2):154-7. PubMed ID: 7249498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.
    Pedersen LE; Bonde J; Graudal NA; Backer NV; Hansen JE; Kampmann JP
    Br J Clin Pharmacol; 1987 Jan; 23(1):41-6. PubMed ID: 3814461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodologic factors influencing plasma binding of alpha-1-acid glycoprotein-bound and albumin-bound drugs.
    Morse DS; Abernethy DR; Greenblatt DJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):535-9. PubMed ID: 3934087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to human serum.
    Belpaire FM; Bogaert MG; Rosseneu M
    Eur J Clin Pharmacol; 1982; 22(3):253-6. PubMed ID: 6125395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of aprindine and moxaprindine to human serum, alpha 1-acid glycoprotein and serum of healthy and diseased humans.
    Teirlynck O; Belpaire FM; Andreasen F
    Eur J Clin Pharmacol; 1982; 21(5):427-31. PubMed ID: 7075647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein binding of itraconazole and fluconazole in patients with chronic renal failure.
    Arredondo G; Martinez-Jorda R; Calvo R; Aguirre C; Suarez E
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):361-4. PubMed ID: 7952798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of glycyrrhizic acid on protein binding of diltiazem, verapamil, and nifedipine.
    Lee KJ; Park HJ; Shin YH; Lee CH
    Arch Pharm Res; 2004 Sep; 27(9):978-83. PubMed ID: 15473671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gallopamil binding to human serum proteins.
    Rutledge DR; Pieper JA
    Eur J Clin Pharmacol; 1987; 33(4):375-80. PubMed ID: 3443143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.
    Zini R; Morin D; Salvadori C; Tillement JP
    Br J Clin Pharmacol; 1990 Jan; 29(1):9-18. PubMed ID: 2297464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing serum protein binding of lidocaine in humans.
    McNamara PJ; Slaughter RL; Pieper JA; Wyman MG; Lalka D
    Anesth Analg; 1981 Jun; 60(6):395-400. PubMed ID: 6165258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha 1-Acid glycoprotein and plasma lidocaine binding.
    Shand DG
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():27-31. PubMed ID: 6705424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: implications for binding of drugs.
    Viani A; Rizzo G; Carrai M; Pacifici GM
    Int J Clin Pharmacol Ther Toxicol; 1992 Apr; 30(4):128-33. PubMed ID: 1572757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients.
    Chu JS; Kishion S; Nomura A; Miyazaki K
    Zhongguo Yao Li Xue Bao; 1997 Sep; 18(5):408-10. PubMed ID: 10322928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.